EP1507793A4 - Neutrokine-alpha et variant d'epissage de neutrokine-alpha - Google Patents

Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Info

Publication number
EP1507793A4
EP1507793A4 EP02786413A EP02786413A EP1507793A4 EP 1507793 A4 EP1507793 A4 EP 1507793A4 EP 02786413 A EP02786413 A EP 02786413A EP 02786413 A EP02786413 A EP 02786413A EP 1507793 A4 EP1507793 A4 EP 1507793A4
Authority
EP
European Patent Office
Prior art keywords
neutrokine
alpha
splice variant
variant
alpha splice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02786413A
Other languages
German (de)
English (en)
Other versions
EP1507793A2 (fr
Inventor
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Michael W Laird
Stephen Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1507793A2 publication Critical patent/EP1507793A2/fr
Publication of EP1507793A4 publication Critical patent/EP1507793A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02786413A 2001-10-17 2002-10-16 Neutrokine-alpha et variant d'epissage de neutrokine-alpha Withdrawn EP1507793A4 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32950801P 2001-10-17 2001-10-17
US329508P 2001-10-17
US32974701P 2001-10-18 2001-10-18
US329747P 2001-10-18
US33083501P 2001-10-31 2001-10-31
US330835P 2001-10-31
US33147801P 2001-11-16 2001-11-16
US331478P 2001-11-16
US33672601P 2001-12-07 2001-12-07
US336726P 2001-12-07
US36854802P 2002-04-01 2002-04-01
US368548P 2002-04-01
PCT/US2002/032910 WO2003033658A2 (fr) 2001-10-17 2002-10-16 Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Publications (2)

Publication Number Publication Date
EP1507793A2 EP1507793A2 (fr) 2005-02-23
EP1507793A4 true EP1507793A4 (fr) 2006-02-01

Family

ID=27559746

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02786413A Withdrawn EP1507793A4 (fr) 2001-10-17 2002-10-16 Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Country Status (4)

Country Link
EP (1) EP1507793A4 (fr)
AU (1) AU2002351495A1 (fr)
CA (1) CA2476675A1 (fr)
WO (1) WO2003033658A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173122B2 (en) 1996-10-25 2012-05-08 Human Genome Sciences, Inc. Methods of treatment using antibodies to neutrokine-alpha
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US9187548B2 (en) 2000-06-16 2015-11-17 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP2332563A3 (fr) 2004-10-13 2013-03-13 The Washington University Utilisation de BAFF pour traiter la sepsie
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ568204A (en) 2005-10-13 2012-01-12 Human Genome Sciences Inc Methods and compositions for use in treatment of patients with autoantibody positive diseases
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
EP2447282B1 (fr) 2006-05-30 2016-01-27 Genentech, Inc. Anti-CD22 Anticorps, immuno-conjugués et utilisations associées
SI2215117T2 (en) 2007-10-30 2018-04-30 Genentech, Inc. Purification of the antibody by cation exchange chromatography
DK2848625T3 (da) 2008-08-14 2019-10-07 Genentech Inc Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
EP3513810A1 (fr) 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions et procédés utiles pour stabiliser des formulations contenant des protéines
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
MX339666B (es) 2010-06-24 2016-06-03 Genentech Inc * Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
JP6605202B2 (ja) 2011-12-22 2019-11-13 ジェネンテック， インコーポレイテッド イオン交換膜クロマトグラフィー
AU2020254582A1 (en) 2019-04-01 2021-09-30 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN110176272B (zh) * 2019-04-18 2021-05-18 浙江工业大学 一种基于多序列联配信息的蛋白质二硫键预测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO2002018620A2 (fr) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO2002018620A2 (fr) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN B P ET AL: "Expression vectors for affinity purification and radiolabeling of proteins using Escherichia coli as host.", GENE. 11 FEB 1994, vol. 139, no. 1, 11 February 1994 (1994-02-11), pages 73 - 75, XP002356741, ISSN: 0378-1119 *
SCHALLER A ET AL: "Characterization of apxIVA, a new RTX determinant of Actinobacillus pleuropneumoniae.", MICROBIOLOGY (READING, ENGLAND) AUG 1999, vol. 145 ( Pt 8), August 1999 (1999-08-01), pages 2105 - 2116, XP002356740, ISSN: 1350-0872 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173122B2 (en) 1996-10-25 2012-05-08 Human Genome Sciences, Inc. Methods of treatment using antibodies to neutrokine-alpha
US8231873B2 (en) 1996-10-25 2012-07-31 Human Genome Sciences, Inc. Methods of treatment using antibodies to Neutrokine-alpha
US8303951B2 (en) 1996-10-25 2012-11-06 Human Genome Sciences, Inc. Neutrokine-alpha antibodies and methods of use thereof
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US9187548B2 (en) 2000-06-16 2015-11-17 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma

Also Published As

Publication number Publication date
EP1507793A2 (fr) 2005-02-23
AU2002351495A1 (en) 2003-04-28
CA2476675A1 (fr) 2003-04-24
WO2003033658A3 (fr) 2004-05-27
WO2003033658A2 (fr) 2003-04-24

Similar Documents

Publication Publication Date Title
EP1157110A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EP1507793A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
EP1425162A4 (fr) Materiaux et dispositifs optiques
AU9667901A (en) Mycoattractants and mycopesticides
EP1368909A4 (fr) Systeme et procedes de localisation
EP1309718A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EP1463742A4 (fr) Nouvelles pyrazolo-pyrimidines et pyrrolo-pyrimidines et leur utilisation
AU2002234643A1 (en) Amphoteric liposomes and the use thereof
EP1408978A4 (fr) Nouvelles phenylamino-pyrimidines et leur utilisation
IL154553A0 (en) Urocortin-iii and uses thereof
GB2376073B (en) Fluid-gauging systems and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
EP1392317A4 (fr) 1-benzazepines substituees et leurs derives
EP1408985A4 (fr) Nouveaux pyridopyrimidones et leurs utilisations
GB2382598B (en) Construction and elongate members therefor
GB0028589D0 (en) Optical devices and methods
AU2002227019A1 (en) Cashcalling and voicemining system
EP1367123A4 (fr) Neurotonine et utilisation
HK1046707A1 (zh) 中性活動(NEUTROKINE)-α與中性活動-α粘接變異
AU2002354710A1 (en) Q9ul33/q9nzz4 and q9h5p3 splice variants
GB0129444D0 (en) Property marketing and conveyancy system
GB0213055D0 (en) Ground and ceiling advertisement unit
AU2002240498A1 (en) Protected deoxyadenosines and deoxyguanosines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040517

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20051220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060321